Nevertheless, these results are in accordant with clinical observations, ALT and AST do not rise in 79% of NAFLD patients [43], and their levels are poor indicators of diagnosis of NAFLD [27]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.